Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions

Autor: Douglas A. Mata, Jamal K. Benhamida, Andrew L. Lin, Chad M. Vanderbilt, Soo-Ryum Yang, Liliana B. Villafania, Donna C. Ferguson, Philip Jonsson, Alexandra M. Miller, Viviane Tabar, Cameron W. Brennan, Nelson S. Moss, Martin Sill, Ryma Benayed, Ingo K. Mellinghoff, Marc K. Rosenblum, Maria E. Arcila, Marc Ladanyi, Tejus A. Bale
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Acta Neuropathologica Communications, Vol 8, Iss 1, Pp 1-13 (2020)
Druh dokumentu: article
ISSN: 2051-5960
DOI: 10.1186/s40478-020-01058-6
Popis: Abstract A subset of glioblastomas (GBMs) harbors potentially druggable oncogenic FGFR3-TACC3 (F3T3) fusions. However, their associated molecular and clinical features are poorly understood. Here we analyze the frequency of F3T3-fusion positivity, its associated genetic and methylation profiles, and its impact on survival in 906 IDH-wildtype GBM patients. We establish an F3T3 prevalence of 4.1% and delineate its associations with cancer signaling pathway alterations. F3T3-positive GBMs had lower tumor mutational and copy-number alteration burdens than F3T3-wildtype GBMs. Although F3T3 fusions were predominantly mutually exclusive with other oncogenic RTK pathway alterations, they did rarely co-occur with EGFR amplification. They were less likely to harbor TP53 alterations. By methylation profiling, they were more likely to be assigned the mesenchymal or RTK II subclass. Despite being older at diagnosis and having similar frequencies of MGMT promoter hypermethylation, patients with F3T3-positive GBMs lived about 8 months longer than those with F3T3-wildtype tumors. While consistent with IDH-wildtype GBM, F3T3-positive GBMs exhibit distinct biological features, underscoring the importance of pursuing molecular studies prior to clinical trial enrollment and targeted treatment.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje